MA47494A - Nouvelles utilisations d'anticorps anti-sirpg - Google Patents

Nouvelles utilisations d'anticorps anti-sirpg

Info

Publication number
MA47494A
MA47494A MA047494A MA47494A MA47494A MA 47494 A MA47494 A MA 47494A MA 047494 A MA047494 A MA 047494A MA 47494 A MA47494 A MA 47494A MA 47494 A MA47494 A MA 47494A
Authority
MA
Morocco
Prior art keywords
new uses
sirpg antibodies
sirpg
antibodies
new
Prior art date
Application number
MA047494A
Other languages
English (en)
Inventor
Vanessa Gauttier
Caroline Mary
Sabrina Pengam
Nicolas Poirier
Virginie Thepenier
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MA47494A publication Critical patent/MA47494A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
MA047494A 2017-02-17 2018-02-15 Nouvelles utilisations d'anticorps anti-sirpg MA47494A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305184 2017-02-17

Publications (1)

Publication Number Publication Date
MA47494A true MA47494A (fr) 2019-12-25

Family

ID=58185462

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047494A MA47494A (fr) 2017-02-17 2018-02-15 Nouvelles utilisations d'anticorps anti-sirpg

Country Status (11)

Country Link
US (2) US20190382483A1 (fr)
EP (1) EP3583128A1 (fr)
JP (3) JP7179743B2 (fr)
KR (1) KR20190117670A (fr)
CN (1) CN110300764A (fr)
AU (1) AU2018221774C1 (fr)
BR (1) BR112019016356A2 (fr)
CA (1) CA3051318A1 (fr)
IL (1) IL268731B2 (fr)
MA (1) MA47494A (fr)
WO (1) WO2018149938A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268731B2 (en) * 2017-02-17 2025-07-01 Ose Immunotherapeutics New uses of anti-SIRPG antibodies
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
JP7713447B2 (ja) 2019-11-27 2025-07-25 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための組み合わせ療法
AU2021267943A1 (en) * 2020-05-08 2022-11-24 Electra Therapeutics, Inc. SIRPα, SIRPβ1, and SIRPy antibodies and uses thereof
JP2023528341A (ja) 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
EP4256336A1 (fr) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimères pour réduire l'interférence de médicaments qui se lient à cd47 dans des dosages sérologiques
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
EP4429768A2 (fr) * 2021-11-10 2024-09-18 Electra Therapeutics, Inc. Anticorps sirp gamma et leurs utilisations
CA3253030A1 (fr) 2022-06-01 2023-12-07 ALX Oncology Inc. Polythérapies pour le traitement du carcinome urothélial

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB0607943D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Biomarkers for chronic transplant dysfunction
EP1930342B1 (fr) 2006-12-04 2012-01-25 Institut Pasteur OB-fold utilisé en tant que base pour l'ingénierie de nouveaux liants spécifiques
CA2785139A1 (fr) 2009-12-22 2011-06-30 Novartis Ag Proteine hybride tetravalente a region constante d'anticorps anti-cd-47 a utiliser en therapie
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
SG11201607143UA (en) * 2014-03-11 2016-09-29 Univ Leland Stanford Junior Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
US20180281938A1 (en) * 2015-01-22 2018-10-04 Sikorsky Aircraft Corporation Low noise rotor blade design
CN107530354A (zh) 2015-04-21 2018-01-02 吉利德科学公司 使用syk抑制剂对慢性移植物抗宿主病的治疗
US9845345B2 (en) 2015-05-18 2017-12-19 Ab Initio Biotherapeutics, Inc. SIRP polypeptide compositions and methods of use
JOP20190009A1 (ar) * 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP3559037A1 (fr) 2016-12-22 2019-10-30 Wake Forest University Health Sciences Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
EA201891882A1 (ru) * 2017-02-17 2019-07-31 Осе Иммьюнотерапьютикс НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ
IL268731B2 (en) * 2017-02-17 2025-07-01 Ose Immunotherapeutics New uses of anti-SIRPG antibodies

Also Published As

Publication number Publication date
WO2018149938A1 (fr) 2018-08-23
JP2025184966A (ja) 2025-12-18
KR20190117670A (ko) 2019-10-16
JP2023010810A (ja) 2023-01-20
IL268731A (en) 2019-10-31
IL268731B1 (en) 2025-03-01
JP2020510643A (ja) 2020-04-09
BR112019016356A2 (pt) 2020-04-07
IL268731B2 (en) 2025-07-01
JP7179743B2 (ja) 2022-11-29
AU2018221774B2 (en) 2024-08-22
US12331115B2 (en) 2025-06-17
CA3051318A1 (fr) 2018-08-23
EP3583128A1 (fr) 2019-12-25
AU2018221774A1 (en) 2019-08-08
US20220242951A1 (en) 2022-08-04
AU2018221774C1 (en) 2025-01-09
US20190382483A1 (en) 2019-12-19
CN110300764A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
EP3762030A4 (fr) Anticorps anti-cd73 et utilisations associées
EP3838289A4 (fr) Anticorps anti-tigit et ses utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA49043A (fr) Formulation stable d'anticorps
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3370770A4 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
EP3735427A4 (fr) Anticorps anti-mct1 et utilisations associées
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3359573A4 (fr) Marquage d'anticorps
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3733702A4 (fr) Anticorps anti-lag-3 et utilisations associées
EP3883967A4 (fr) Anticorps anti-cd38 et anti-icam1 et utilisations correspondantes
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3681912A4 (fr) Anticorps spécifiques d'axl et leurs utilisations
EP3419599A4 (fr) Formulations d'antagonistes d'il-6 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
MA51147A (fr) Associations d'anticorps anti-c5 et utilisations associées